Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dostarlimab + paclitaxel
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**dostarlimab + paclitaxel** is a combination therapy used in oncology, specifically for the treatment of primary advanced or recurrent endometrial cancer. The regimen typically includes dostarlimab (a programmed death receptor-1 [PD-1]-blocking monoclonal antibody) combined with carboplatin and paclitaxel (chemotherapy), followed by single-agent dostarlimab. However, if only "dostarlimab + paclitaxel" is specified without carboplatin, it may refer to a subset of regimens or off-label use; in clinical practice and regulatory approvals, the standard approved regimen is "dostarlimab + carboplatin + paclitaxel," but sometimes "paclitaxel" alone may be referenced as part of the backbone chemotherapy[2][3][7]. Dostarlimab works by blocking PD-1 on immune cells, thereby enhancing anti-tumor immune responses. Paclitaxel is a microtubule-stabilizing agent that disrupts cell division.
- Other names
- dostarlimab and paclitaxelJemperli plus paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on dostarlimab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dostarlimab + paclitaxel.